Thus, AKT1 mutations have emerged as an attractive druggable target and there is promising clinical data in ER + ductal BC patients harboring AKT1E17K mutation treated with the pan-AKT targeted inhibitors AZD5363, MK-22046, 48 and ipatasertib, another ATP-competitive AKT inhibitor49. Here, AKT1 is linked to breast cancer.